CVE:RX BioSyent (RX) Stock Price, News & Analysis C$10.93 -0.06 (-0.55%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider Trades About BioSyent Stock (CVE:RX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioSyent alerts:Sign Up Key Stats Today's RangeC$10.93▼C$10.9950-Day RangeC$10.84▼C$11.6052-Week RangeC$8.24▼C$12.13Volume500 shsAverage Volume4,481 shsMarket CapitalizationC$125.01 millionP/E Ratio17.74Dividend Yield1.65%Price TargetN/AConsensus RatingN/A Company OverviewBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Read More… Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address RX Stock News HeadlinesInvesting in BioSyent (CVE:RX) five years ago would have delivered you a 110% gainDecember 15, 2024 | uk.finance.yahoo.comBioSyent Inc. (RX.V)November 25, 2024 | finance.yahoo.comTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the global banking system... backed up by Elon Musk and the White House.March 6, 2025 | Stansberry Research (Ad)BioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four DaysNovember 24, 2024 | finance.yahoo.comCalculating The Fair Value Of BioSyent Inc. (CVE:RX)November 22, 2024 | finance.yahoo.comBioSyent Inc. (BIOYF)November 21, 2024 | finance.yahoo.comBioSyent Inc.November 13, 2024 | wsj.comBioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?October 24, 2024 | finance.yahoo.comSee More Headlines RX Stock Analysis - Frequently Asked Questions How have RX shares performed this year? BioSyent's stock was trading at C$11.00 at the start of the year. Since then, RX shares have decreased by 0.6% and is now trading at C$10.93. View the best growth stocks for 2025 here. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) announced its quarterly earnings data on Thursday, May, 25th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.08 by $0.02. The company had revenue of $3.82 million for the quarter, compared to analysts' expectations of $4.80 million. BioSyent had a net margin of 20.60% and a trailing twelve-month return on equity of 20.01%. How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Astec Industries (ASTE), Bank of Nova Scotia (BNS), Carnival Co. & (CCL), Cisco Systems (CSCO), Devon Energy (DVN) and Ford Motor (F). Company Calendar Last Earnings5/25/2017Today3/06/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:RX CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.62 Trailing P/E Ratio17.74 Forward P/E Ratio15.74 P/E GrowthN/ANet IncomeC$7.02 million Net Margins20.60% Pretax MarginN/A Return on Equity20.01% Return on Assets12.86% Debt Debt-to-Equity Ratio2.90 Current Ratio3.92 Quick Ratio6.91 Sales & Book Value Annual SalesC$34.06 million Price / Sales3.67 Cash FlowC$3.55 per share Price / Cash Flow3.07 Book ValueC$3.22 per share Price / Book3.39Miscellaneous Outstanding Shares11,437,447Free FloatN/AMarket CapC$125.01 million OptionableNot Optionable Beta0.93 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (CVE:RX) was last updated on 3/6/2025 by MarketBeat.com Staff From Our Partners77 Hedge Funds Are Betting On This Off-Radar MineralWith surging prices... supply shortages... and growing demand, hedge funds are betting big on potash. In fa...The Tomorrow Investor | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredNew Way To Target 2x Trades Every Monday MorningNo. 1 Stock to Buy for THIS MONDAY Heads up: Tim Bohen’s new algorithm just uncovered a dirt-cheap stock th...StocksToTrade | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | Sponsored2025 AI Blueprint: Nvidia’s more important than everAI is Big Tech’s #1 priority in 2025—Amazon, Microsoft, Google, and Meta are pouring a record $320 billion int...Weiss Ratings | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.